22157.jpg
Adalimumab Global Market Report 2022: Rising Prevalence of Arthritis and Clinical Trials to Spur Growth
22 févr. 2023 09h33 HE | Research and Markets
Dublin, Feb. 22, 2023 (GLOBE NEWSWIRE) -- The "Adalimumab Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028: Segmented By Type (Biologics v/s Biosimilars), By...
180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology
29 avr. 2022 18h32 HE | 180 Life Sciences Corp.
The study achieved the primary endpoint of reduction in nodule hardness at 12 months and secondary endpoint of reduction in nodule size at multiple time points including 12 monthsThe treatment arm...
22157.jpg
Global Crohn's Disease Forecast and Market Analysis Report 2020-2027 - Despite Formulary Constraints, Novel Pipeline Drugs will Expand the Market
12 janv. 2021 07h03 HE | Research and Markets
Dublin, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The "Crohn's Disease Forecast and Market Analysis to 2027" report has been added to ResearchAndMarkets.com's offering. As specialty products, therapies...
•EnosiLifeSciences-Logo-Main-BlueGrey.png
Enosi Life Sciences Files Patent for TNF-Inhibiting Molecules EN1001, EN2001 and EN3001
18 nov. 2020 09h00 HE | Enosi Life Sciences
SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Enosi Life Sciences Corp. (“Enosi” or the “Company”), a drug research and development company focused on providing industry-leading therapeutics for...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira and UCB Announce Start of Phase 3 Program for CIMZIA(R) (certolizumab pegol) in Psoriasis
08 janv. 2015 02h00 HE | Dermira, Inc.
Phase 3 program aims to address patient need for alternative treatment options in moderate-to-severe psoriasis   Program includes the first Phase 3 study in psoriasis comparing two...